NSAIDs — Mechanisms and Toxicity

• COX Enzyme Inhibition and Prostaglandin Depletion: NSAIDs inhibit both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, which catalyze the conversion of arachidonic acid to prostaglandin H2 (PGH2), a precursor for various prostaglandins (PGE2, PGI2, PGF2α) and thromboxane A2 (TXA2). COX-1 is constitutively expressed in most tissues and produces prostaglandins responsible for homeostatic functions including gastric mucosal protection, platelet aggregation, and renal hemodynamics. COX-2 is primarily inducible at sites of inflammation and produces prostaglandins mediating pain, fever, and inflammation. Nonselective NSAIDs inhibit both isoenzymes; selective COX-2 inhibitors (coxibs) such as celecoxib preferentially target COX-2, theoretically reducing gastrointestinal toxicity while maintaining some anti-inflammatory efficacy. However, preferential COX-2 inhibition eliminates protective PGI2 (prostacyclin) in vascular endothelium while leaving TXA2-mediated platelet aggregation relatively intact, shifting the TXA2/PGI2 balance toward prothrombosis and explaining the increased cardiovascular risk associated with selective COX-2 inhibitors.

• Gastrointestinal Toxicity Mechanisms: Prostaglandins, particularly PGE2 and PGI2, normally maintain gastric mucosal integrity through multiple mechanisms: (1) stimulation of mucus and bicarbonate secretion via EP3 and IP receptors on gastric epithelial cells, creating a protective mucous layer; (2) maintenance of gastric blood flow through vasodilation, ensuring adequate oxygen delivery and nutrient supply to mucosa; (3) inhibition of gastric acid secretion through suppression of parietal cell H+ secretion; and (4) promotion of mucosal cell proliferation and epithelial barrier function. COX inhibition depletes gastric PGE2 and PGI2, eliminating these protective mechanisms and exposing the mucosa to direct acid damage. This leads to acute erosions, ulceration, and potential hemorrhage. Increased gastric acid penetration of the mucus layer triggers inflammatory cascades, recruitment of neutrophils, and release of proteolytic enzymes and reactive oxygen species, deepening tissue injury. Additionally, NSAIDs impair platelet aggregation through TXA2 inhibition, impairing hemostatic plug formation and exacerbating bleeding from ulcerated sites. Risk is amplified by concurrent Helicobacter pylori infection, which causes chronic inflammation and compromises mucosal defenses, and by proton pump inhibitor (PPI) or H2-receptor antagonist co-administration, which reduces acid-related damage but does not address prostaglandin depletion.

• Renal Toxicity Mechanisms: In the kidney, prostaglandins (particularly PGE2 and PGI2) maintain renal hemodynamics through vasodilation of afferent arterioles and regulation of renin release from juxtaglomerular cells. COX inhibition reduces renal prostaglandin synthesis, causing afferent arteriolar vasoconstriction, decreased glomerular filtration rate (GFR), and reduced renal blood flow—effects that are typically reversible upon NSAID discontinuation but may progress to acute kidney injury (AKI) in susceptible patients. Prostaglandins also promote sodium and water excretion through inhibition of collecting duct aquaporin-2 expression; their depletion causes sodium retention and volume expansion, further compromising renal perfusion in volume-depleted states. Additionally, NSAIDs impair the tubuloglomerular feedback mechanism by decreasing renin secretion, reducing angiotensin II-mediated constriction of efferent arterioles and thereby lowering intraglomerular pressure. In patients with borderline renal perfusion—including those with chronic kidney disease, congestive heart failure (CHF), hepatic cirrhosis, sepsis, or volume depletion—these effects precipitate acute decompensation. Chronic NSAID use can cause analgesic nephropathy, a form of chronic interstitial nephritis resulting from cumulative tubular toxicity, papillary necrosis, and chronic inflammation, ultimately leading to end-stage renal disease (ESRD).

• Cardiovascular Toxicity Mechanisms: Selective COX-2 inhibition and, to a lesser extent, nonselective NSAID use increase cardiovascular risk through multiple overlapping mechanisms. First, preferential inhibition of endothelial COX-2 reduces PGI2 (a potent vasodilator and antiplatelet agent), while platelet COX-1 activity (responsible for TXA2 production) is relatively preserved, creating a prothrombotic state. Second, NSAIDs promote sodium and fluid retention, increasing intravascular volume and preload, which elevates blood pressure and cardiac workload—effects particularly deleterious in patients with underlying hypertension or CHF. Third, NSAIDs may directly impair myocardial contractility and promote arrhythmias through effects on cardiac potassium channels and calcium handling. Fourth, NSAIDs increase systemic vascular resistance through inhibition of vasodilatory prostaglandins and may activate the renin-angiotensin-aldosterone system (RAAS). Fifth, NSAIDs increase sympathetic tone and heart rate, augmenting myocardial oxygen demand. The net result is increased risk for acute myocardial infarction (MI), stroke, and heart failure exacerbation, with risk increasing proportionally with dose and duration of use, and substantially elevated in patients with pre-existing coronary artery disease, diabetes, or significant cardiovascular risk factors.

• Platelet and Coagulation Effects: NSAIDs inhibit platelet TXA2 synthesis, reducing platelet aggregation and increasing bleeding risk—effects that are reversible for nonselective NSAIDs (since platelet COX-1 is inhibited) and irreversible for aspirin (which acetylates COX-1, permanently inactivating platelet function for the platelet lifespan of 7-10 days). NSAIDs also reduce plasma fibrinogen levels and may impair clotting factor synthesis. These effects are particularly concerning in patients on concurrent anticoagulation or antiplatelet therapy and in perioperative settings.

• Hepatotoxicity Mechanisms: NSAIDs undergo hepatic metabolism and can cause acute hepatotoxicity through direct toxic effects on hepatocytes (particularly with diclofenac and ibuprofen) or immune-mediated liver injury. Mechanisms include oxidative stress from reactive metabolite formation, mitochondrial dysfunction, and triggering of apoptotic pathways. Chronic NSAID use may rarely cause cirrhosis or chronic hepatitis.

• Age ≥65 Years: Older adults have substantially increased risk for NSAID-induced gastrointestinal bleeding (5-10 fold increased incidence), renal complications, and cardiovascular events. This reflects age-related reductions in gastric mucosal blood flow, impaired gastric acid buffering, increased baseline cardiovascular disease prevalence, and age-related decline in renal function and autoregulation. Advanced age is the single most powerful predictor of serious NSAID complications and mandates careful risk stratification and gastroprotection.

• History of Peptic Ulcer Disease (PUD) or Gastrointestinal Bleeding: Patients with prior PUD or upper gastrointestinal (GI) hemorrhage have dramatically increased risk (10-15 fold) for recurrent bleeding with NSAID exposure. This reflects baseline mucosal damage, impaired healing mechanisms, and heightened susceptibility to NSAID-induced mucosal injury. H. pylori seropositivity confers additional risk.

• Concurrent Anticoagulation or Antiplatelet Therapy: Simultaneous use of warfarin, direct oral anticoagulants (DOACs), or antiplatelet agents (aspirin, clopidogrel, ticagrelor) substantially increases bleeding risk through multiple mechanisms: NSAIDs impair platelet function, reduce clotting factor synthesis, and may inhibit metabolism of warfarin (increasing INR). The combination increases GI bleeding risk by 5-10 fold and is generally contraindicated except in specific high-risk cardiovascular scenarios requiring careful monitoring and gastroprotection.

• Chronic Kidney Disease (CKD): Baseline renal impairment (eGFR <60 mL/min/1.73 m²) substantially increases risk for NSAID-induced acute kidney injury and progressive renal deterioration. The kidneys' dependence on prostaglandins for autoregulation becomes critical in CKD, where compensatory mechanisms are exhausted. NSAIDs are generally avoided or used at minimal doses with frequent monitoring in patients with eGFR <30 mL/min/1.73 m².

• Congestive Heart Failure (CHF), Hepatic Cirrhosis, or Volume Depletion States: These conditions create "prerenal" states in which renal perfusion is critically dependent on prostaglandin-mediated vasodilation and maintenance of effective circulating volume. NSAIDs precipitate acute decompensation, fluid retention, hypertension, and acute kidney injury. NSAIDs are relatively contraindicated in CHF and should be avoided entirely in decompensated states.

• Diabetes Mellitus: Diabetic patients have enhanced susceptibility to NSAID-induced renal injury due to pre-existing diabetic nephropathy, impaired renal autoregulation, and reduced GFR reserve. Combined with increased cardiovascular risk, NSAIDs should be used cautiously and only when necessary, with gastroprotection and frequent renal function monitoring.

• Cardiovascular Risk Factors or Established Coronary Artery Disease: Patients with hypertension, prior MI or stroke, diabetes, significant smoking history, or hyperlipidemia have substantially increased risk for NSAID-induced acute cardiovascular events. The relative risk for MI and stroke increases 2-4 fold with NSAID use and rises further with nonselective NSAIDs and selective COX-2 inhibitors. Duration and dose of use amplify risk.

• Infection, Sepsis, or Inflammatory States: Acute infections and systemic inflammatory states augment prostaglandin dependence for maintaining renal perfusion and immune homeostasis. NSAIDs in these settings increase risk for acute kidney injury and may paradoxically worsen infection outcomes through immunosuppression.

• Dehydration or Concurrent Diuretic Use: Volume depletion increases renal dependence on prostaglandins for maintaining glomerular filtration. NSAIDs in volume-depleted patients, or in patients on concurrent loop or thiazide diuretics, substantially increase AKI risk.

• Drug-Drug Interactions Affecting Renal Function: Concurrent use of ACE inhibitors (ACEi) or angiotensin receptor blockers (ARBs) with NSAIDs forms a "triple whammy" (especially when combined with diuretics), critically reducing renal perfusion and markedly increasing AKI risk through overlapping mechanisms of renin-angiotensin system suppression and reduced intravascular volume.

• NSAID Type and Dose: Higher cumulative doses and longer duration of use increase risk proportionally. Selective COX-2 inhibitors carry increased cardiovascular risk compared to nonselective NSAIDs. Indomethacin and diclofenac carry higher GI and renal toxicity risk; naproxen may carry slightly lower cardiovascular risk than other nonselective NSAIDs, though debate persists. Aspirin at high doses carries all NSAID toxicities plus irreversible antiplatelet effects.

Gastrointestinal Manifestations

• Dyspepsia and Epigastric Discomfort: Classic NSAID-induced GI symptoms include burning epigastric pain, bloating, early satiety, and nausea. These symptoms correlate imperfectly with mucosal damage and may occur without ulceration or conversely may be absent in patients with advanced erosive disease or bleeding ulcers—a critical clinical trap, as absence of GI symptoms does not exclude serious pathology. Physiologically, symptoms reflect direct irritation from reduced gastric pH buffering, mucosal inflammation, and delayed gastric emptying from inhibition of antral prostaglandins.

• Upper Gastrointestinal Hemorrhage: Presents acutely with hematemesis (bright red or "coffee ground" appearance), melena (black tarry stools), or hematochezia (bright red per rectum, unusual for upper GI sources). Patients may present with syncope, presyncope, or hemodynamic instability reflecting acute blood loss. Tachycardia, orthostatic hypotension, pallor, and signs of shock indicate severe hemorrhage. Laboratory findings show acute anemia (drop in hemoglobin), elevated blood urea nitrogen (BUN) with preserved creatinine initially (BUN/Cr ratio >20:1) reflecting intraluminal blood protein catabolism. Pathophysiology involves ulcer erosion into mucosal vasculature with breaching of hemostatic mechanisms, compounded by NSAID-induced platelet dysfunction impairing clot formation.

• Gastric Perforation: Represents a surgical emergency manifesting with acute, severe epigastric pain radiating to the back, often with peritoneal signs (rigidity, rebound tenderness, absent bowel sounds). Patients may develop rapid progression to septic shock if untreated. Occurs when NSAID-induced ulcers erode completely through the gastric wall. Plain radiographs reveal free intra-abdominal air ("pneumoperitoneum") visible as a crescent-shaped lucency under the diaphragm on upright chest X-ray—a pathognomonic finding requiring emergent surgical consultation.

Renal Manifestations

• Acute Kidney Injury (AKI): Presents with rising serum creatinine, reduced urine output (oliguria <400 mL/day or non-oliguric with preserved urine output but rising creatinine), elevated BUN, and hyperkalemia (from reduced renal potassium excretion and aldosterone suppression). Oligaric AKI typically develops within days to weeks of NSAID initiation or dose escalation, particularly in predisposed patients. Urine sodium is characteristically low (<10 mEq/L), and fractional excretion of sodium (FENa) is low (<1%), reflecting prerenal physiology. Urinalysis may show bland findings or mild proteinuria; granular casts may be present if interstitial nephritis develops. Renal ultrasound shows normal-sized kidneys without obstruction (distinguishing prerenal AKI from postrenal obstruction). NSAID-induced AKI is usually reversible upon drug discontinuation if recognized early, though some degree of residual renal dysfunction may persist if damage was severe.

• Hyperkalemia: Develops from two mechanisms: (1) reduced renal potassium secretion due to decreased GFR, and (2) NSAID-induced suppression of aldosterone synthesis through renin-angiotensin-aldosterone system inhibition, impairing distal tubular potassium secretion. Presents with weakness, palpitations, and cardiac arrhythmias if severe (K+ >6.0 mEq/L). ECG changes include peaked T waves, prolonged PR intervals, and widened QRS complexes in severe hyperkalemia. Risk is amplified in diab

Gastrointestinal (COX-1/prostaglandin depletion)

• Ulcer complications: the American College of Gastroenterology recommends risk stratification before chronic NSAID therapy, co-prescription of a PPI (or misoprostol, a PGE1 analog that directly replaces the depleted prostaglandin) in high-risk patients, and test-and-treat for H. pylori before starting long-term NSAIDs. Monitor CBC for iron-deficiency anemia. Misoprostol is an abortifacient and is contraindicated in pregnancy.
• NSAID enteropathy: distal small-bowel erosions and diaphragm-like strictures causing occult blood loss; not prevented by acid suppression, since the lesion is prostaglandin-dependent rather than acid-dependent.

Renal

• Hemodynamic AKI: afferent arteriolar constriction; monitor creatinine, potassium, and blood pressure. KDIGO advises avoiding NSAIDs in advanced CKD.
• Acute interstitial nephritis with minimal change disease: an immunologic reaction producing nephrotic-range proteinuria; unlike beta-lactam AIN, fever, rash, and eosinophilia are often absent. Treatment is drug withdrawal, with corticosteroids in selected cases.
• Papillary necrosis: medullary ischemia from loss of vasodilatory prostaglandins; hematuria and flank pain, classically with analgesic abuse, diabetes, or sickle cell disease.

• The "triple whammy": NSAID + ACEI/ARB + diuretic is the classic stem for drug-induced AKI. Afferent constriction, blocked efferent constriction, and volume depletion converge; the single best next step is to stop the NSAID and restore volume, not to image or biopsy.
• Nephrotic syndrome plus AKI in an NSAID user = minimal change disease with acute interstitial nephritis. The examiner's trap is expecting the classic AIN triad of fever, rash, and eosinophilia — it is usually absent with NSAIDs.
• Asthma + nasal polyps + aspirin-triggered bronchospasm = Samter triad (aspirin-exacerbated respiratory disease). Mechanism is COX blockade shunting arachidonic acid into the leukotriene pathway; a leukotriene receptor antagonist is the logical answer.
• Aspirin in a febrile child with a viral illness → Reye syndrome (encephalopathy plus microvesicular hepatic steatosis from mitochondrial injury). Kawasaki disease is the accepted exception in which aspirin is still used.
• Ibuprofen taken before aspirin occupies the COX-1 channel and prevents irreversible acetylation, blunting aspirin's cardioprotection — a recognized FDA interaction. Aspirin should be taken first.
• Salicylate overdose produces a mixed respiratory alkalosis and anion-gap metabolic acidosis with tinnitus. Sodium bicarbonate for serum and urine alkalinization is the answer; hemodialysis is reserved for severe toxicity. Nonsalicylate NSAID overdose has no antidote.
• Indomethacin closes a PDA; prostaglandin E1 keeps it open. The same physiology explains why FDA and ACOG advise against NSAIDs after 20 weeks of gestation.
• Common distractor: assuming celecoxib is "safe." It reduces ulcer risk relative to nonselective agents but still carries the FDA boxed thrombotic warning, still causes renal toxicity, and is contraindicated in the perioperative CABG period. Similarly, do not assume a PPI protects the small bowel — it does not.